Aeterna Zentaris Inc. (AEZS)
| Market Cap | 9.03M |
| Revenue (ttm) | 6.86M |
| Net Income (ttm) | -23.37M |
| Shares Out | 4.86M |
| EPS (ttm) | -4.81 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 16,512 |
| Open | 1.88 |
| Previous Close | 1.93 |
| Day's Range | 1.86 - 1.94 |
| 52-Week Range | 1.36 - 3.94 |
| Beta | 2.08 |
| Analysts | Strong Buy |
| Price Target | 15.00 (+706.45%) |
| Earnings Date | Nov 9, 2023 |
About AEZS
Aeterna Zentaris Inc., a specialty biopharmaceutical company, engages in developing and commercializing therapeutics and diagnostic tests. Its lead product is Macrilen (macimorelin), an orally available peptidomimetic ghrelin receptor (GHSR-1a) agonist that stimulates the secretion of growth hormone by binding to the GHSR-1a for the diagnosis of adult growth hormone deficiency and childhood-onset growth hormone deficiency, as well as oncology indications; and AEZS-150, a delayed clearance parathyroid hormonefusion polypeptide that is in preclin... [Read more]
Financial Performance
In 2022, AEZS's revenue was $5.64 million, an increase of 7.22% compared to the previous year's $5.26 million. Losses were -$22.73 million, 171.6% more than in 2021.
Financial StatementsAnalyst Forecast
According to one analyst, the rating for AEZS stock is "Strong Buy" and the 12-month stock price forecast is $15.0.
News
AEZS Stock Alert: Halper Sadeh LLC Is Investigating Whether the Merger of Aeterna Zentaris Inc. Is Fair to Shareholders
NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating whether the merger of Aeterna Zentaris Inc. (NASDAQ: AEZS) and Ceapro Inc. is fair to Aeterna shareholders. H...
Aeterna Zentaris and Ceapro Announce Merger of Equals to Create a Diversified Biopharmaceutical Company
TORONTO and EDMONTON, Dec. 14, 2023 (GLOBE NEWSWIRE) -- Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) (“Aeterna”) and Ceapro Inc. (TSXV: CZO) (OTCQX: CRPOF) (“Ceapro”), two innovative biopharmaceut...
Aeterna Zentaris Reports Second Quarter 2023 Financial Results
TORONTO, ONTARIO, Aug. 09, 2023 (GLOBE NEWSWIRE) -- Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) (“Aeterna” or the “Company”), a specialty biopharmaceutical company developing and commercializing ...
Aeterna Zentaris Outlines Progress on Development Pipeline Programs and Provides Corporate Update
TORONTO, ONTARIO, July 13, 2023 (GLOBE NEWSWIRE) -- Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) (“Aeterna” or the “Company”), a specialty biopharmaceutical company developing and commercializing ...
Aeterna Zentaris to Participate in the Virtual Investor Summer Spotlight Series
Live moderated video webcast on Thursday, July 13 th at 10:00 AM ET TORONTO, ONTARIO, July 05, 2023 (GLOBE NEWSWIRE) -- Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) (“Aeterna” or the “Company”), a...
Aeterna Zentaris Announces Results of Virtual 2023 Meeting of Shareholders
TORONTO, ONTARIO, June 14, 2023 (GLOBE NEWSWIRE) -- Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) ("Aeterna" or the "Company"), a specialty biopharmaceutical company developing and commercializing ...
Aeterna Zentaris Reports First Quarter 2023 Financial Results
– Ended the quarter with $ 46 . 6 million in cash, expected to fund operations into 2025
Aeterna Zentaris Provides Update on Macrilen® (Macimorelin), Reiterates Advancement of Pediatric DETECT Trial
TORONTO, ONTARIO, April 05, 2023 (GLOBE NEWSWIRE) -- Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) (“Aeterna” or the “Company”), a specialty biopharmaceutical company developing and commercializing...
Aeterna Zentaris Reports Fourth Quarter and Full Year 2022 Financial Results
– Company ended the year with $50.6 million in cash, expected to fund operations through 2024 and into 2025 – Executing strategy to streamline advancement of development programs, build upon growing b...
Pharmanovia to Market GHRYVELIN™ (Macimorelin) in the European Economic Area (EEA) and UK as Diagnostic Test for Growth Hormone Deficiency (GHD)
TORONTO, ONTARIO, March 16, 2023 (GLOBE NEWSWIRE) -- Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) (“Aeterna” or the “Company”), a specialty biopharmaceutical company developing and commercializing...
Aeterna Zentaris Provides Business Update and Outlines Key Upcoming Milestones
TORONTO, ONTARIO, Jan. 17, 2023 (GLOBE NEWSWIRE) -- Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) (“Aeterna” or the “Company”), a specialty biopharmaceutical company developing and commercializing ...
Aeterna Zentaris to Present at the Virtual Investor 2023 Companies to Watch Event
Live video webcast on Thursday , January 19 th at 3 :00 PM ET
Aeterna Zentaris Reports Third Quarter 2022 Financial Results
– Company ended the quarter with $ 53.8 million in cash
Aeterna Zentaris Set to Regain Full Rights to Macrilen™ (Macimorelin) in U.S. and Canada from Novo Nordisk
– Company plans to prioritize efforts to identify new strategic development and commercialization partner
Aeterna Zentaris Reports Second Quarter 2022 Financial Results and Recent Highlights
– Company ended the quarter with $58.2 million in cash
Aeterna Zentaris Announces Effective Date of Share Consolidation
TORONTO, ON, July 18, 2022 (GLOBE NEWSWIRE) -- Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) (“Aeterna” or the “Company”), a specialty biopharmaceutical company commercializing and developing thera...
Aeterna Zentaris Announces Shareholder Approval of Share Consolidation
TORONTO, ONTARIO, July 15, 2022 (GLOBE NEWSWIRE) -- Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) ("Aeterna" or the "Company"), a specialty biopharmaceutical company developing and commercializing ...
Aeterna Zentaris Announces Further Adjournment of Shareholder Meeting
TORONTO, ONTARIO, July 06, 2022 (GLOBE NEWSWIRE) -- Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) ("Aeterna" or the "Company"), a specialty biopharmaceutical company developing and commercializing ...
Aeterna Zentaris Announces Results of Annual Meeting of Shareholders
- Vote to approve share consolidation adjourned to July 6, 2022
Aeterna Zentaris to Present at the H.C. Wainwright Global Investment Conference
TORONTO, ONTARIO, May 18, 2022 (GLOBE NEWSWIRE) -- Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) (“Aeterna” or the “Company”), a specialty biopharmaceutical company developing and commercializing a...
Update on Positive Pre-Clinical Results from AIM Biologicals Development Program for the Potential Treatment of Parkinson's Disease
– Data presented at IMMUNOLOGY2022 ™ , the A nnual Event of the American Association of Immunologists
Aeterna Zentaris Reports First Quarter 2022 Financial Results and Provides Business Outlook
– C ontinue d advancement across di versified development pipeline
Aeterna Zentaris Abstract Accepted for Presentation at IMMUNOLOGY2022™, the Annual Event of the American Association of Immunologists
– Company advancing development of its Autoimmunity Modifying AIM Biologic al s as a potential therapeutic treatment option for Parkinson's Disease (" PD "), a neurodegenerative movement disorder
Aeterna Zentaris Secures New European Patent Related to Use of Macimorelin for the Diagnosis of Growth Hormone Deficiency in Adults
– Strengthens intellectual property portfolio for macimorelin and the commercial product Ghryvelin ® / Macrilen ™ in Europe as the Company plans to pursue even greater protection
JTC Team Announces Continuation of its Virtual Investor Spotlight Series with NASDAQ: AEZS, NASDAQ: CNSP, and NASDAQ: AREC
- Live video webcast events on Thursday, April 14 at 10 AM ET, 11:30 AM ET and 1 PM ET - FRENCHTOWN, NJ / ACCESSWIRE / April 13, 2022 / JTC Team ("JTC"), a fully integrated corporate communications an...